chronic constipation chronic constipation
Conditions
Interventions
To take Macrogol 4000
D046650
Sponsors
Okuyama Masatsugu
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: In order to be eligible for participation in this study, the patient must: 1.be given adequate explanation about the study, fully understand it, and voluntarily agree to participate by giving written informed consent. 2.be able and willing to follow instructions, make protocol-defined visits, undertake protocol-defined assessments, and report his/her symptoms. 3.be 20 years and over of age at the point of informed consent. 4.be diagnosed as chronic constipation
Exclusion criteria
Exclusion criteria: The patient must be excluded from participating in the study if the patient: 1.is complicated by a severe cardiopulmonary disorder. 2.has any condition in which one or both of the study drugs (Macrogol 4000) is contraindicated according to the contraindications listed in the drugs' package inserts, or has past history of hypersensitivity to any components of the drugs. 3.participated in other clinical trial and received other investigational drugs within one month prior to the start (first dose) of study treatment of this study. 4.took Macrogol 4000 within 3 months of participation in this study 5.is lactating or potentially pregnant. 6.is considered to be inappropriate to participate in the study for any other reason by the PI/subinvestigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| patient satisfaction | — |
Secondary
| Measure | Time frame |
|---|---|
| defecation frequency serum magnesium level The Bristol Stool Form Scale modified Constipation Scoring System (mCCS) Patient Assessment of Constipation Quality of Life Questionnaire (PAC-QOL) | — |
Contacts
Public ContactMasatsugu Okuyama
Kashiwara Municipal Hospital
Outcome results
None listed